By Sheeba M. | May 02, 2026
Canadian Cannabis: Green Shoots in a Mature Market
The Canadian cannabis market spent the last three years digesting oversupply and slashed valuations. But something’s shifting. Licensed producers are actually making money again, and the smart ones are looking beyond North America.
The Pivot to Profitability
Canopy Growth has trimmed fat, refocused on higher-margin products (beverages, edibles), and is finally showing positive EBITDA. Tilray is doing the same—cutting SKUs, consolidating brands, and focusing on retail partnerships that stick.
The result: margins that actually look respectable. Where LPs were burning cash in 2023-2024, they’re now managing cash flow and paying down debt. It’s not sexy, but it’s real.
The Real Opportunity: International
Canopy Growth has Germany, Australia, and Spain on the radar. Organigram is quietly expanding medical distribution across Europe. This is where LPs can actually grow revenue—not fighting for shelf space in a saturated domestic market, but building supply agreements in countries where medical cannabis is finally getting legal.
Expect announcements on EU supply deals and partnerships this spring. First-mover advantage in European medical supply is worth billions.
The Contrarian View
Canadian LPs are still deeply out of favor with retail investors, which means valuations are cheap for patient capital. If you believe rescheduling in the US eventually unlocks M&A with Canadian players, or that EU medical supply deals create new revenue streams, now is the time to accumulate.
Sources
- Reuters – Canadian LP earnings and international expansion news
- SEC Filings – Canadian LP quarterly financial reports
Related Articles
Track cannabis stocks with the Weedstock Real-Time Tracker